Cilique® – Bioequivalent to Cilest®

Cilique contraceptive packet

  • Contains 35 mcg ethinylestradiol and 250 mcg norgestimate, the same active ingredients as Cilest® and has effectively replaced Cilest® which is no longer available 1,2
  • Indicated for the prevention of pregnancy in women who elect to use oral contraception 1,2
  • Causes changes in the endometrium and cervical mucus 1,2
  • Reliable, highly effective and well tolerated oral contraceptive when taken correctly 1
  • Side effects may include depressed mood and depression.1

CILIQUE ®  is suitable for use in the following patient groups: 3,4

  • Women who want autonomy and control over their menstrual cycle
  • Women aged up to 50 years with no other medical conditions
  • Women ≥6 months postpartum if fully breastfeeding
  • Women ≥6 weeks postpartum if not breastfeeding
  • Women with dysmenorrhoea who have an irregular, heavy or prolonged bleeding pattern
  • Women with endometriosis


  1. Cilique® SPC
  2. Cilest® SPC available at
  3. Faculty of Sexual and Reproductive Health Care (FSRH). UK Medical Eligibility Criteria for Contraceptive Use. UKMEC 2016. London: FSRH, 2016.
  4. WHO Guidelines. Medical Eligibility Criteria for contraceptive use 2015 update

IE/OCS/0119/0101(1)(1) Date of Preparation: June 2021

Web design by